FDA’s Quality Metrics Initiative Challenged on Enforceability
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical industry won’t let FDA force it to report quality metrics without a fight.
You may also be interested in...
US FDA Quality Metrics Initiative Continues Moving Forward … Quietly
Despite few public announcements and industry concerns, FDA's Office of Pharmaceutical Quality director says program is not dead.
ICMRA’s Pilot On Hybrid Inspections And CMC Changes Seeks Participants
Driven by COVID-19 pandemic challenges, regulatory authorities from multiple regions want to work with sponsors on new joint approaches for expediting manufacturing changes globally and streamlining preapproval and pre-licensing inspections.
US FDA Would Allow Separation Alternatives In Manufacture Of Low-Risk Beta-Lactams
Proposed guidance revision adds nuance to manufacturing facility separation expectations for beta-lactam compounds that pose less risk of anaphylaxis than penicillin and related antibiotics.